Eiger Biopharmaceuticals LLC is a United States-based commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed OTC Markets Other stock markets 23:27:07 27/09/2024 HKT			5-day change	1st Jan Change
8.500 ^USD	-.--%		-.--%	-

01/10/24	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
30/09/24	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI

Market Cap	12.59M 11M 10.11M 9.43M 17.88M 1.2B 18.15M 121M 47.19M 589M 47.25M 46.23M 2.03B	P/E 2022	-0.51x	P/E 2023	-0.13x
Enterprise Value	27.95M 24.43M 22.45M 20.93M 39.69M 2.66B 40.3M 270M 105M 1.31B 105M 103M 4.51B	EV / Sales 2022	-836,796x	EV / Sales 2023	1,605,487x
Free-Float	86.47%	Yield 2022 *	-	Yield 2023	-

01/10/24	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
30/09/24	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI
05/09/24	Combined Hearing for Disclosure Statement and Plan Approved for Eiger BioPharmaceuticals, Inc.	CI
05/09/24	Fifth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
04/09/24	First Motion for Exclusivity Period Extension Approved For Eiger BioPharmaceuticals, Inc.	CI
03/09/24	Fourth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
03/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
03/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
03/09/24	Eiger InnoTherapeutics, Inc. completed the acquisition of Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.	CI
28/08/24	Third Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
21/08/24	Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	CI
15/08/24	Second Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
05/08/24	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	CI

30/08/23	Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
30/06/23	Baird Adjusts Price Target on Eiger BioPharmaceuticals to $5 From $3, Maintains Outperform Rating	MT
07/09/22	BTIG Adjusts Eiger BioPharmaceuticals' Price Target to $48 from $57, Maintains Buy Rating	MT
11/10/21	EIGER BIOPHARMACEUTICALS : Wedbush Suspended Coverage on Eiger BioPharmaceuticals	MT
11/05/21	EIGER BIOPHARMACEUTICALS : Citigroup Adjusts Price Target on Eiger BioPharmaceuticals to $26 From $23, Maintains Buy Rating	MT

Eiger BioPharmaceuticals Stock

Stocks

EIGR

US28249U2042

Biotechnology & Medical Research

Valuation: Eiger BioPharmaceuticals

Latest news : Eiger BioPharmaceuticals

Analysts' recommendations: Eiger BioPharmaceuticals

Press Releases: Eiger BioPharmaceuticals

News in other languages: Eiger BioPharmaceuticals

Course Extremes

Managers and Directors: Eiger BioPharmaceuticals

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

01/10/24	Eiger BioPharmaceuticals : DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE Form 8 K	PU
16/07/24	Eiger BioPharmaceuticals : THIS IS NOT A SOLICITATION OF ACCEPTANCE OR REJECTION OF THE PLAN. THE DEBTORS ARE SEEKING APPROVAL OF THE DISCLOSURE STATEMENT ON A CONDITIONAL BASIS, BUT IT HAS NOT YET BEEN APPROVED BY THE BANKRUPTCY COURT Form 8 K	PU
11/07/24	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist with FDA Breakthrough Therapy Designation	AQ
06/05/24	Sentynl Therapeutics Announces Global Acquisition of Zokinvy for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals	AQ
01/04/24	Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection	AQ

Manager	Title	Age	Since
Christopher Kurtz CTO	Chief Tech/Sci/R&D Officer	59	18/04/2022
Douglas Staut PRN	Corporate Officer/Principal	-	19/04/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/10/23	Propel Bio Management LLC	Buy	Company	278,239	0.6281%
31/10/23	Propel Bio Management LLC	Buy	Company	24,332	0.0549%
18/10/23	Propel Bio Management LLC	Other	Company	4,367,100	9.8588%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EIGER BIOPHARMACEUTICALS	-.--%	-.--%	-.--%	-59.75%	12.59M
LONZA GROUP AG	+1.70%	+6.73%	+2.48%	+7.78%	49.15B
REVOLUTION MEDICINES, INC.	+0.92%	+6.21%	+408.85%	+607.44%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+11.06%	+25.75%	-7.89%	34.55B
BEONE MEDICINES AG	+5.46%	+8.10%	+21.83%	+66.94%	33.09B
CELLTRION, INC.	+3.96%	+6.07%	+14.14%	+37.68%	25.19B
ASCENDIS PHARMA A/S	+2.51%	+4.94%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+7.24%	+71.03%	+132.17%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.35%	+13.41%	+18.82%	13.83B
ICON PUBLIC LIMITED COMPANY	-1.14%	+7.52%	+14.75%	-30.83%	13.26B
Average	+1.45%	+4.82%	+63.58%	+85.82%	24.23B
Weighted average by Cap.	+1.72%	+5.25%	+89.02%	+131.72%

	2022	2023
Net sales	13.48 11.79 10.83 10.1 19.15 1.28K 19.44 130.05 50.56 631.09 50.61 49.53 2.17K	15.77 13.79 12.67 11.81 22.4 1.5K 22.74 152.13 59.14 738.22 59.21 57.93 2.54K
Net income	-96.78M -84.6M -77.75M -72.47M -137M -9.21B -140M -933M -363M -4.53B -363M -355M -15.61B	-74.96M -65.53M -60.22M -56.14M -106M -7.14B -108M -723M -281M -3.51B -281M -275M -12.09B
Net Debt	-63.29M -55.33M -50.85M -47.4M -89.9M -6.03B -91.26M -610M -237M -2.96B -238M -232M -10.21B	15.36M 13.43M 12.34M 11.5M 21.82M 1.46B 22.15M 148M 57.59M 719M 57.65M 56.41M 2.48B

3 years	1.1	28.5
5 years	1.1	300.64
10 years	1.1	618.9